Implantable left ventricular assist devices: An evolving long-term cardiac replacement therapy

Annals of Surgery

Volumn 226, Issue 4, 1997, Pages 461-470

  DeRose, Joseph J ^a   Argenziano, Michael ^a   Sun, Benjamin C ^a   Reemtsma, Keith ^a   Oz, Mehmet C ^a   Rose, Eric A ^a  

^a Department of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INOTROPIC AGENT; NITRIC OXIDE;

ADOLESCENT; ADULT; AGED; ARTICLE; ASSISTED CIRCULATION; CARDIOGENIC SHOCK; FEMALE; GRAFT INFECTION; HEART FAILURE; HEART LEFT VENTRICLE; HEART RIGHT VENTRICLE FAILURE; HEART TRANSPLANTATION; HOSPITAL DISCHARGE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OUTPATIENT CARE; PRIORITY JOURNAL; SCHOOL CHILD; SURVIVAL TIME; THROMBOEMBOLISM; TREATMENT OUTCOME;

AMBULATORY CARE; CARDIOMYOPATHIES; CAUSE OF DEATH; HEART-ASSIST DEVICES; HOSPITALIZATION; HUMANS; PATIENT SELECTION; SHOCK, CARDIOGENIC; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 0031461068     PISSN: 00034932     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000658-199710000-00007     Document Type: Article

References (22)

1. Schocken DD, Arrieta MI, Leaverton PE, Ross EA. Prevalence and Mortality Rate of Congestive Heart Failure in the United States. J Am Coll Cardiol 1992; 20:301-306.
2. Smith WM. Epidemiology of congestive heart failure. Am J Cardiol 1985; 55:3A.
3. Funk D. Epidemiology of End-Stage Heart Disease in The Artificial Heart: Prototypes, Policies, and Patients/Committee to Evaluate the Artificial Heart Program of the National Heart, Lung, and Blood Institute. In: Hogness JR, Van Antwerp M, eds. Washington, DC: National Academy Press; 1991:251-261.
4. O'Connell JB, Bristow MR. Economic impact of heart failure in the United States: time for a new approach. J Heart Lung Transplant 1993; 13:S107-110.
5. Solvd T. Effect of enalapril on survival in patients with reduced ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325:293-302.
6. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med 1987; 316:1429-1435.
7. United Network for Organ Sharing (UNOS). Annual Report of the U.S. Scientific Registry for Organ Transplantation and the Organ Procurement and Transplantation Network: U.S. Department of Health and Human Services, 1993.
8. Oz MC, Argenziano M, Catanese K, et al. Bridge experience with long term implantable left ventricular assist devices: are they an alternative to transplantation ? Circulation 1996; 95:1844-1852.
9. Frazier OH, Rose EA, Macmanus Q, et al. Multicenter clinical evaluation of the HeartMale 1000 IP left ventricular assist device. Ann Thorac Surg 1992; 53:1080-1090.
10. McCarthy PM. Heartmate implantable left ventricular assist device: bridge to transplantation and future applications. Ann Thorac Surg 1995; 59(2 Suppl):S46-51.
11. Frazier OH, Rose EA, McCarthy P, et al. Improved mortality and rehabilitation of transplant candidates treated with a long-term implantable left ventricular assist system. Ann Surg 1995; 222:327-336.
12. Morrone TM, Buck LA, Catanese KA, et al. Early progressive mobilization of left ventricular assist device patients is safe and optimizes recovery prior to cardiac transplant. J Heart Lung Transplant 1996; 15:423-429.
13. Rose EA, Goldstein DJ. Wearable long-term mechanical support for patients with end-stage heart disease: a tenable goal. Ann Thorac Surg 1996; 61:399-402.
14. Catanese KA, Goldstein DJ, Williams DL, et al. Outpatient left ventricular assist device support: a destination rather than a bridge. Ann Thorac Surg 1996; 62:646-653.
15. Spanier TB, Rose S, Schmidt AM, Itescu S. Interactions between dendritic cells and T cells on the surface of left ventricular assist devices leads to a TH2 pattern of cytokine production and B cell hyperreactivity in vivo. Circulation 1996; 94:I-293.
16. Rose EA, Levin HR, Oz MC, et al. Artificial circulatory support with textured interior surfaces: a counter-intuitive approach to minimize thromboembolism. Circulation 1994; 90(part 2):II87-II91.
17. Slater JP, Rose EA, Levin HR, et al. Low thromboembolic risk without anticoagulation using advanced-design left ventricular assist devices. Ann Thorac Surg 1996; 62:1321-1328.
18. Oz MC, Goldstein DJ, Pepino P, et al. Selection scale predicts patients successfully receiving long-term, implantable left ventricular assist devices. Circulation 1995; 92(suppt II):II-169-173.
19. Goldstein DJ, Seldomridge JA, Chen JM, et al. Use of aprotinin in LVAD recipients reduces blood loss, blood product requirement, and perioperative mortality. Ann Thorac Surg 1995; 59:1063-1068.
20. Frazier OH, Rose EA, McCarthy P, et al. Improved mortality and rehabilitation of transplant candidates treated with a long-term implantable left ventricular assist system. Ann Surg 1995; 222:327-338.
21. Kendall K, Sharp JW, McCarthy PM. Quality of life for hospitalized implantable LVAD patients. J Heart Lung Transplant 1994; 13:S72-76.
22. Pennington DG. Extended support with permanent systems: percutaneous versus totally implantable. Ann Thorac Surg 1996; 61:403-406.